Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jan 20;13(2):1729-1741.
doi: 10.18632/aging.202535. Epub 2021 Jan 20.

Anserine, HClO-scavenger, protected against cognitive decline in individuals with mild cognitive impairment

Nobutaka Masuoka  1 , Chenxu Lei  1 , Haowei Li  1 , Noriko Inamura  2   3 , Shigenobu Shiotani  4 , Nobuya Yanai  4 , Kenichiro Sato  4 , Keisuke Sakurai  1 , Tatsuhiro Hisatsune  1
Affiliations
Randomized Controlled Trial

Anserine, HClO-scavenger, protected against cognitive decline in individuals with mild cognitive impairment

Nobutaka Masuoka et al. Aging (Albany NY). .

Abstract

Neuroinflammation has been recognized as a promising target when considering strategies for treating AD. In particular, it has been shown that neutrophils and MPO-mediated neuroinflammatory responses with the production of HClO play a role in the progression of AD. In this study, we aimed to evaluate the effects of anserine, a scavenger of HClO, on the protection of cognitive declines in persons with MCI. Fifty-eight elderly volunteers were screened, and 36 MCI individuals were assigned either to an active arm, who received 500 mg anserine per day, or a placebo arm, for 12-weeks. To assess cognitive function, we performed MMSE at baseline and after the ingestion. The data of the MMSE for 30 subjects who completed the follow-up tests were analyzed. A significant difference was detected in the change score of MMSE between the active arm (1.9 ± 2.0; n = 15) and the placebo arm (0 ± 2.8; n = 15) (p = 0.036). After the correction with the daily intake of anserine, the significance was elevated (p = 0.0176). Our results suggest that anserine protects elderly persons with MCI from cognitive declines by suppressing MPO-mediated neuroinflammatory responses.

Keywords: Alzheimer’s disease; anserine; hypochlorous acid; mild cognitive impairment; myeloperoxidase.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: The authors declare a conflicts of interest in the AUTHOR CONTRIBUTIONS and FUNDING sections.

Figures

Figure 1
Figure 1
Flow diagram showing the number of subjects during the study. Baseline test: The test at the start of the intervention. Follow-up test: The test at twelve weeks after the start.
Figure 2
Figure 2
Anserine as a scavenger for hypochlorous acid, HClO. HClO (5.0mM), HO · (10mM), ONOO · (5.0mM). R: Reference protein, C: Control, A: Anserine, F: FA, V: VC, M: Mixture.
Figure 3
Figure 3
The distribution of the MMSE scores change. A dot shows the points of individual improvement. A bar shows the average in the placebo-administered subjects or the anserine-administered subjects and ± Standard Deviation.
Figure 4
Figure 4
The concentration of blood anserine after ingestion. Dots and bars show the average ± Standard Deviation.
Figure 5
Figure 5
The concentration of blood CRP (C-Reactive Protein) after the anserine treatment. Dots show the data of the individuals. Bars show the average ± Standard Deviation.
See this image and copyright information in PMC

References

    1. World Health Organization. Towards a dementia plan: a WHO guide. 2018. https://apps.who.int/iris/bitstream/handle/10665/272642/9789241514132-en...
    1. Alzheimer’s Association. 2012 Alzheimer’s disease facts and figures. Alzheimers Dement. 2012; 8:131–68. 10.1016/j.jalz.2012.02.001 - DOI - PubMed
    1. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, et al. , and Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer ’ s Association on ” The Preclinical State of AD “ ; July 23, 2015; Washington DC, USA. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016; 12:292–323. 10.1016/j.jalz.2016.02.002 - DOI - PMC - PubMed
    1. Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte AI, Giusti P, Zusso M, Robert P, Frisoni GB, Cattaneo A, Zille M, Boltze J, Cartier N, et al. Current and emerging avenues for Alzheimer’s disease drug targets. J Intern Med. 2019; 286:398–437. 10.1111/joim.12959 - DOI - PubMed
    1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7:280–92. 10.1016/j.jalz.2011.03.003 - DOI - PMC - PubMed

Publication types